Product image of Mibg (123i) Curium Netherlands (Iobenguane Sulfate I-123) supplied by GNH India

Mibg (123i) Curium Netherlands

Active Ingredient:
Iobenguane Sulfate I-123
Origin:
EU

Mibg (123i) Curium Netherlands (Iobenguane Sulfate I-123)

Iobenguane Sulfate I-123, the active ingredient in Mibg (123i) Curium Netherlands, is a radiopharmaceutical presented as an injectable solution for intravenous use. It is employed in diagnostic imaging to assess sympathetic nervous system activity, particularly in neuroendocrine and cardiac evaluations.

GNH India supplies Mibg (123i) Curium Netherlands as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to global quality standards and provides reliable logistics for radiopharmaceuticals to oncology centres, nuclear medicine departments and imaging facilities across multiple regions.

Manufacturer / TM Owner

Curium Netherlands B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Iobenguane Sulfate I-123 is used in diagnostic imaging of adrenergic tissue and related disorders.

  • Pheochromocytoma: enables scintigraphic localization of catecholamine‑producing tumors.
  • Neuroblastoma: assists in staging and treatment planning by visualizing tumor uptake.
  • Cardiac sympathetic innervation: assesses myocardial sympathetic nerve integrity for risk stratification.

How It Works

  • Iobenguane Sulfate I-123 is taken up by adrenergic tissue via the norepinephrine transporter (NET). Once internalized, the I-123 radionuclide emits gamma photons that are captured by a gamma camera, producing high‑resolution scintigraphic images of sympathetic nervous system activity and neuroendocrine tumor distribution.

Side Effects

Adverse reactions may occur following intravenous administration of Iobenguane Sulfate I-123.

Common Side Effects

  • Nausea: mild, transient feeling of stomach upset.
  • Flushing: temporary reddening of the skin.
  • Headache: mild to moderate intensity.
  • Transient hypertension: short‑lived increase in blood pressure.
  • Injection site pain: mild discomfort at the venipuncture site.
  • Dizziness: brief episodes of light‑headedness.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic reaction requiring immediate medical attention.
  • Severe hypotension: marked drop in blood pressure.
  • Radiation‑induced tissue injury: localized damage at high cumulative doses.
  • Cardiac arrhythmia: irregular heart rhythm potentially life‑threatening.
  • Pulmonary edema: fluid accumulation in the lungs.
  • Thyroid dysfunction: abnormal thyroid hormone levels due to iodine exposure.

Precautions & Warnings

Prior to use, clinicians should evaluate specific safety considerations.

  • Pregnancy: avoid unless the diagnostic benefit outweighs potential fetal radiation risk.
  • Breastfeeding: discontinue nursing or ensure adequate iodine blockade if continuation is necessary.
  • Renal impairment: assess renal function as reduced clearance may increase radiation exposure.
  • Thyroid blocking: consider administering stable iodine to reduce thyroid uptake of free iodine.
  • Radiation safety: follow ALARA principles to protect staff and other patients.
  • Store at ambient temperature: keep in original lead‑shielded container, protect from light, do not freeze.

Avoid Interactions

Iobenguane Sulfate I-123 may interact with other agents that affect sympathetic imaging.

Major Interactions (Avoid)

  • Concurrent radiopharmaceuticals: can interfere with image interpretation.
  • Beta‑blockers: may diminish tracer uptake in adrenergic tissue.
  • Iodine‑containing contrast agents: may alter biodistribution of free iodine.

Moderate Interactions (Monitor Closely)

  • Antihypertensive drugs: monitor for blood pressure fluctuations during imaging.
  • Chemotherapeutic agents affecting norepinephrine transporters: observe potential changes in tracer localization.
  • Sympathomimetic agents: may increase background activity and affect image quality.

Frequently Asked Questions

Iobenguane Sulfate I-123 is used as a diagnostic imaging agent to visualize adrenergic tissue. It helps locate neuroendocrine tumors such as pheochromocytoma and neuroblastoma, and it assesses cardiac sympathetic nerve integrity for risk stratification.

The compound is taken up by cells that express the norepinephrine transporter. The I-123 radionuclide then emits gamma photons, which are captured by a gamma camera to produce detailed images of sympathetic nervous system activity and tumor distribution.

The administered activity is determined by the prescribing physician based on the specific clinical indication, patient size, and imaging protocol. Dosing is expressed in megabecquerels (MBq) and is individualized for each examination.

Data are limited, and the radiopharmaceutical delivers ionising radiation. It should be avoided in pregnancy unless the diagnostic benefit clearly outweighs the risk. Breastfeeding mothers should discontinue nursing or use appropriate iodine blockade if continuation is essential.

Enquiries are submitted via the product page on gnhindia.com, where you specify the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

The most common alternative is I-131 labeled MIBG, which emits higher‑energy beta particles and provides therapeutic as well as imaging capabilities. I-123 offers superior image quality, lower radiation dose to the patient, and is preferred when purely diagnostic information is required.

The product should be stored at ambient temperature, protected from light, and kept in its original lead‑shielded container. It must not be frozen or shaken, and handling should follow radiation safety protocols to limit exposure.

It is administered intravenously by a qualified nuclear medicine professional. The radiopharmaceutical is typically diluted in a sterile saline solution and injected as a single bolus, after which imaging is performed at a defined time interval.

Serious risks include severe allergic reactions (anaphylaxis), significant blood pressure changes (hypotension or hypertension), radiation‑induced tissue injury, cardiac arrhythmias, and, in rare cases, thyroid dysfunction due to free iodine release.

Patients with known hypersensitivity to the product, those who are pregnant unless absolutely necessary, individuals with uncontrolled severe hypertension, and patients who cannot comply with radiation safety measures should not receive this radiopharmaceutical.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Iobenguane Sulfate I-123

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT